Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, ...
BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain ...
SHELTON, Conn.--(BUSINESS WIRE)--PerkinElmer, a global leader in analytical solutions and specialized services for (bio)pharma, applied and food markets, today announced the acquisition of Project ...
Aelis Farma has launched its Phase IIb clinical trial evaluating AEF0217, targeting behavioural and cognitive impairments in individuals with Down syndrome (Trisomy 21). Recruitment for the trial is ...
Aelis Farma SA ((FR:AELIS)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results